论文部分内容阅读
目的:研究中分子羟乙基淀粉在急性脑分水岭梗死治疗中的作用。方法:选取我院收治的急性脑分水岭梗死患者128例,采取数字随机法分成观察组和对照组。对照组采取常规治疗,对照组在常规治疗基础上加用中分子羟乙基淀粉治疗,比较两组临床效果。结果:观察组治疗后7 d、14 d的BI、DNS评分均高于对照组,且治疗后评分均高于治疗前,差异均具有统计学意义(P<0.05)。对照组治疗后14 d的BI、DNS评分高于治疗前,差异有统计学意义(P<0.05)。观察组良好率64.06%,不良率35.94%,对照组良好率23.44%,不良率76.56%,观察组良好率高于对照组,不良率低于对照组,差异有统计学意义(P<0.05)。两组患者未发生严重不良反应。结论:中分子羟乙基淀粉可提高急性脑分水岭梗死常规治疗效果,改善患者神经功能缺损程度,提高良好率,是优秀的治疗药物之一。
Objective: To study the role of hydroxyethyl starch in the treatment of acute cerebral infarction. Methods: A total of 128 acute cerebral infarction patients admitted to our hospital were selected and randomly divided into observation group and control group. The control group to take conventional treatment, the control group on the basis of conventional treatment plus the use of molecular hydroxyethyl starch treatment, the clinical efficacy of the two groups were compared. Results: The BI and DNS scores of the observation group were higher than those of the control group on the 7th day and the 14th day after treatment, and the scores after treatment were all higher than those before treatment (P <0.05). The score of BI and DNS on the 14th day after treatment in the control group was significantly higher than that before treatment (P <0.05). The good rate in the observation group was 64.06%, the non-performing rate was 35.94%, the good rate in the control group was 23.44% and the non-performing rate was 76.56%. The good rate in the observation group was higher than that in the control group, the rate of non-performing rate was lower than that in the control group (P <0.05) . Two groups of patients without serious adverse reactions. Conclusion: Hydroxyethyl starch can enhance the routine treatment of acute cerebral infarction, improve the degree of neurological deficits and improve the rate of good, which is one of the best therapeutic drugs.